Answers are grounded in this paper and cite their sources.
Data suggest that low-dose interleukin-2 therapy improves regulatory T cell recovery in patients with inflammatory myopathies, indicating a potential treatment approach.
Our data suggest that shortage of IL-2 is pathophysiologically relevant in PM/DM. Recovery and expansion of Treg by low-dose IL-2 therapy could thus be a promising targeted treatment option.
No takes yet. Share an insight, caveat, or question.
Ohmes et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: